Oncology Research

PNC-27

Targeted anti-cancer peptide (p53-derived) causing tumor necrosis

Overview

PNC-27 is a synthetic peptide containing the p53 binding domain (residues 12-26) fused to a transmembrane-penetrating sequence. It is engineered to selectively kill cancer cells by targeting HDM-2 proteins abnormally expressed on their membranes. Upon binding, it creates pores that destroy the tumor cell (necrosis) while leaving healthy cells unharmed. It is effective even in cancers with mutant p53.

Chemical Information

IUPAC Name

p53(12-26)-Transmembrane Domain Fusion

Sequence

Pro-Pro-Leu-Ser-Gln-Etc (Fusion Sequence)

Molecular Mass

4031.7 Da

Formula

C188H293N53O54S2

Chemical Structure not available

Mechanism of Action

Functions as a membranolytic agent that exploits a specific vulnerability in cancer cells: the presence of HDM-2 on the cell membrane. In normal cells, HDM-2 is nuclear; in cancer cells, it is often overexpressed and found on the surface. PNC-27 binds to this membrane-bound HDM-2 via its p53 leader sequence. Upon binding, the peptide undergoes a conformational change, assembling into transmembrane pores (holes). This breaches the cell membrane, causing an influx of ions and water that leads to rapid necrosis (cell bursting). Because normal cells lack membrane-bound HDM-2, they remain completely unaffected. Crucially, this mechanism is p53-independent, meaning it kills tumors even if their p53 gene is mutated or absent.

Potential Research Fields

Solid Tumors (Breast, Colon, Pancreatic)LeukemiaChemo-resistanceMembrane Biology

Recent Research

Research confirms PNC-27 as a highly selective 'necrotic agent.' Unlike chemotherapy which induces apoptosis (programmed cell death) and can fail if the apoptosis genes (like p53) are broken, PNC-27 acts physically to punch holes in the cancer cell. Recent studies highlight its efficacy across a broad spectrum—from solid tumors like pancreatic and ovarian cancer to liquid tumors like leukemia. Current investigations focus on its safety profile, repeatedly showing that it spares healthy bone marrow and epithelial cells, making it a promising candidate for targeted therapy with minimal systemic side effects.

Bibliography / Scientific References

[1]PNC-27 anticancer peptide: mechanism and specificity
Cancer Chemother Pharmacol • 2010 (Pivotal) - Established the pore-forming mechanism on HDM-2 membranes.
[2]Efficacy against leukemia cell lines
Anticancer Res • 2020 - Confirmed cytotoxicity in hematologic malignancies.

Related Peptides

No related peptides found.

Peptide Information Guide

Administration Type

Injectable (Subcutaneous/Tumoral)

Injectable administration protocol for research.

Vial Strength

10mg

Reconstitution

Reconstitute with 2ml bacteriostatic water

Dosage Options

1 mg (20 units)

Daily

Protocol for 10mg vial reconstituted w/ 2ml water

Schedule

1x daily

Timing: One specific day.

Duration

6 Weeks

Potential Side Effects

Injection site inflammation

moderatecommon

Research Use Only

This information is for research purposes only. Always consult with a healthcare professional before starting any peptide protocol. Individual responses may vary, and proper medical supervision is recommended for all peptide therapies.